A Phase 4 clinical trial involving glatiramer changed status as of August 31, 2026. The trial, titled "Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS," registered as NCT03535298, is now listed as active but not recruiting.
The study is being conducted at the Phase 4 level, meaning it involves an already approved therapy studied further in a real world or post marketing context. According to the current registry status, the trial is no longer enrolling new participants but continues to follow those already enrolled.
No results have been posted for this trial at this time. The listing does not provide efficacy or safety outcomes, and none should be inferred from the status update alone. The change reflects only where the study stands in its lifecycle, not any conclusion about the therapies being compared.
Readers interested in this trial can review the full record through the official clinical trial registry listing for further details on design, enrollment, and outcome measures as they become available. For more background on glatiramer itself, see the compound overview.